Raghuram Selvaraju

Raghuram “Ram” Selvaraju, Ph.D. – Head of Healthcare Equity Research

Raghuram “Ram” Selvaraju is Head of Healthcare Equity Research, Aegis Capital Corp., with 12 years of total experience in the biotech and pharmaceutical sectors. Dr. Selvaraju started his career in 2000 at the Serono Pharmaceutical Research Institute in Geneva, Switzerland, the applied research arm of Serono, Europe’s largest biopharmaceutical firm at the time. He began his research analyst career five years later in 2005 at Rodman & Renshaw; was senior vice president and Head of Healthcare Equity Research at Hapoalim Securities, the New York broker/dealer subsidiary of Israel’s largest financial services group, Bank Hapoalim, from 2009 to 2010; was a senior biotech analyst at Noble Financial Group in 2010-March 2011; most recently, he was senior vice president and senior biotechnology analyst for one year at Morgan Joseph TriArtisan LLC. He joined Aegis Capital Corp. as Managing Director and Head of Healthcare Equity Research in March 2012. Dr. Selvaraju has been quoted in such publications as The Wall Street Journal, MSN Money, Barron’s, Bloomberg Businessweek, Reuters, Streetwise Reports, BioWorld Today, The Pink Sheet, PharmaVoice and BioCentury, and has also made multiple appearances on Bloomberg TV, Bloomberg Radio and CNBC, discussing biotech and pharmaceuticals stocks and the outlook for the healthcare industry. He has been ranked by StarMine based on earnings estimate accuracy and his team at Rodman & Renshaw was ranked #1 in The Wall Street Journal’s annual “Best On The Street” survey among biotechnology analysts based on overall portfolio return. He has published highly-regarded sector reports on Alzheimer’s disease, Multiple Sclerosis, stroke, orphan neurological disorders, and the most comprehensive Wall Street research produced to date on U.S. healthcare reform policy. Among his academic qualifications, Dr. Selvaraju holds a Bachelor of Science in Biological Sciences and Technical Writing from Carnegie Mellon University, a Doctorate in Cell Biology and Neuroscience, a Master’s of Science in molecular biology from the University of Geneva in Switzerland, and an M.B.A. from Cornell University’s accelerated one-year program for scientists and engineers. Dr. Selvaraju has also published articles in leading peer-reviewed journals, presented research at various scientific conferences, and is a co-inventor on several drug development patents.